semaglutide or tirzepatide. Troubling Findings in Study of GLP-1 Compounders Tirzepatide vs Semaglutide: A Comprehensive

In post hoc analyses of the randomised clinical controlled LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial, patients assigned to GLP-1RAs (liraglutide) had a reduced risk of prostate cancer (HR 0.54, 95% CI 0.34, 0.88) compared with patients assigned to placebo in addition to standard care

The Butsch data showed deficiencies roughly doubling between the 6- and 12-month marks

[1] The slowed gastric emptying and reduced gut motility can lead to harder stools, decreased frequency of bowel movements, and difficulty passing stools

However, a healthcare provider can offer valuable advice on proper injection techniques, suggest alternative injection sites, or provide recommendations for soothing the skin, if necessary